Department of Neuroscience, Neuromed Institute, Pozzilli, IS, Italy.
Radiat Oncol. 2011 Dec 2;6:167. doi: 10.1186/1748-717X-6-167.
Radiotherapy (RT) remains an effective treatment in patients with acromegaly refractory to medical and/or surgical interventions, with durable tumor control and biochemical remission; however, there are still concerns about delayed biochemical effect and potential late toxicity of radiation treatment, especially high rates of hypopituitarism. Stereotactic radiotherapy has been developed as a more accurate technique of irradiation with more precise tumour localization and consequently a reduction in the volume of normal tissue, particularly the brain, irradiated to high radiation doses. Radiation can be delivered in a single fraction by stereotactic radiosurgery (SRS) or as fractionated stereotactic radiotherapy (FSRT) in which smaller doses are delivered over 5-6 weeks in 25-30 treatments. A review of the recent literature suggests that pituitary irradiation is an effective treatment for acromegaly. Stereotactic techniques for GH-secreting pituitary tumors are discussed with the aim to define the efficacy and potential adverse effects of each of these techniques.
放射治疗（RT）仍然是一种有效的治疗方法，适用于对药物和/或手术干预无反应的肢端肥大症患者，可实现持久的肿瘤控制和生化缓解；然而，仍存在对延迟生化效应和潜在放射治疗迟发性毒性的担忧，尤其是高垂体功能减退症发生率。立体定向放射治疗已发展为一种更精确的照射技术，具有更精确的肿瘤定位，从而减少了正常组织（尤其是大脑）受到高剂量辐射的体积。立体定向放射外科（SRS）可以单次分割给予放射治疗，也可以分次立体定向放射治疗（FSRT），在 5-6 周内分 25-30 次给予较小剂量。对近期文献的回顾表明，垂体照射是肢端肥大症的有效治疗方法。本文讨论了生长激素分泌性垂体瘤的立体定向技术，旨在确定这些技术的疗效和潜在不良反应。
